Oncothyreon (ONTY) Misses Q4 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jefferies Starts Oncothyreon (ONTY) at Buy; Sees 49% Upside
March 12, 2015 6:42 AM EDTJefferies initiates coverage on Oncothyreon (NASDAQ: ONTY) with a Buy rating and a price target of $2.50, suggesting 49% upside to yesterday's close.
Analyst Biren Amin commented, "ONTY's ONT-380 has shown encouraging efficacy in PI trials and differentiates itself from competitors on safety. ONTY is further... More
